SABS

SAB Biotherapeutics, Inc. (SABS) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies (hIgG) for immune system disorders. The company's lead candidate, SAB-142, is a human anti-thymocyte globulin (ATG) designed to prevent or delay the progression of Type 1 Diabetes (T1D). The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Revenue dropped to zero from $0.9 million in Q1 2024 due to the termination of the JPEO Rapid Response Contract. The company satisfied all obligations under this grant by December 31, 2024.
• Operating Expenses: Total operating expenses decreased by approximately $1.6 million (12.7%) to $10.8 million.
  • R&D Expenses: Decreased by $0.5 million (6.0%) to $7.7 million. This was driven by significant reductions in outside laboratory services ($0.9M decrease) and facility expenses ($1.2M decrease), partially offset by a $1.1 million increase in clinical trial costs and a $0.9 million increase in salaries and benefits.
  • G&A Expenses: Decreased by $1.1 million (25.6%) to $3.1 million, primarily due to lower salaries, consulting fees, and insurance costs.
• Non-Operating Income: The company recognized a gain of $5.0 million from the change in fair value of warrant liabilities, compared to $5.5 million in the prior year. This gain significantly reduced the net loss.
• Liquidity: Total cash and short-term investments declined by approximately $7.4 million quarter-over-quarter, primarily due to operating cash burn and a net decrease in cash equivalents.

Outlook, Risks, and Management Commentary

• Clinical Progress: Management reported that patient dosing concluded in the last cohort of the Phase 1 clinical study of SAB-142. The drug was generally well-tolerated, with no serum sickness or anti-drug antibodies observed at the target dose. The company plans to advance SAB-142 into a Phase 2b trial in 2025 for adult and pediatric patients with new-onset T1D.
• Going Concern Warning: The company has raised substantial doubt about its ability to continue as a going concern. With an accumulated deficit of $129.4 million and current liquidity of $12.9 million, management expects these resources will not be sufficient to fund operations for more than 12 months from the date of issuance.
• Capital Needs: The company anticipates continued losses and increased expenses as it advances clinical trials. It will require additional capital through equity or debt financings, collaborations, or other funding arrangements. Failure to secure funding could result in scaling back operations, reducing headcount, or ceasing operations.
• Warrant Liabilities: A significant portion of the company's non-operating income is derived from the revaluation of warrant liabilities, which are classified as Level 3 fair value measurements and are subject to volatility based on stock price and other inputs.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for the next fundraising event given the "substantial doubt" disclosure regarding the 12-month liquidity horizon.
• Phase 2b Trial Design: Confirm the enrollment targets, timeline, and estimated costs for the upcoming Phase 2b trial for SAB-142.
• Warrant Liability Volatility: Monitor the fair value of warrant liabilities, as changes in this non-cash item significantly impact the reported net loss and equity position.
• Grant Revenue Status: Confirm if any new government grants or partnership agreements have been secured to replace the terminated JPEO contract revenue.
• Debt Obligations: Review the repayment schedule for the insurance financing note ($139k outstanding) and lease liabilities to ensure no covenant breaches are imminent.